Evidence map›Paper›PMID 33046869›Full record

Trial reportNature medicine2020

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.

Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene Siefker-Radtke, Matthew T Campbell, Rebecca Slack Tidwell, Charles C Guo, Ashish M Kamat, Surena F Matin, John C Araujo and 21 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 7 pooled it
41.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 7 syntheses or guidelines pooled it, 305 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 1 institution in 1 country.

Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. JGao1@mdanderson.org.ORCID http://orcid.org/0000-0001-6138-4472
Neema NavaiDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Omar AlhalabiDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9658-2206
Arlene Siefker-RadtkeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew T CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1915-4491
Rebecca Slack TidwellDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3041-8582
Charles C GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashish M KamatDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Surena F MatinDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John C AraujoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amishi Y ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul CornDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianbo WangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John N PapadopoulosDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shalini S YadavThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jorge M BlandoThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fei DuanThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sreyashi BasuThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5028-3833
Wenbin LiuThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yu ShenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3899-7868
Yuwei ZhangThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marc Daniel MacalusoThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ying WangThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianfeng ChenDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5412-9860
Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8663-2671
Colin DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James P AllisonThe Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangeeta GoswamiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PadSharma@mdanderson.org.ORCID http://orcid.org/0000-0003-4658-055X
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma

Indexed as

AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinomaCisplatinCTLA-4 AntigenFemaleHumansMaleMiddle AgedNeoplasm StagingProgrammed Cell Death 1 ReceptorRisk FactorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCisplatinCTLA-4 AntigenCTLA4 protein, humandurvalumabPDCD1 protein, humanProgrammed Cell Death 1 Receptortremelimumab

Identifiers

PMID33046869
PMCPMC9768836
OpenAlexW3092302767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.